Last edition
News about
Semarion Raises USD 3.8 Million to Scale Cell Assay Technology and Accelerate Pharma Adoption
Semarion raises USD 3.8 million to expand manufacturing and scale its SemaCyte microcarrier platform for pharmaceutical use.
EU Grants Conditional Approval to Rezurock for Chronic GVHD Treatment
European Commission authorises belumosudil for patients aged 12 plus with limited treatment options, marking a significant advance in managing a life-threatening post-transplant condition.
Freudenberg Reports INR 4,427 Crore Sales, Emerges as Key Growth Driver
Freudenberg reports €11.73B in sales and €1.09B operating profit, highlighting strong financial performance with continued investments in R&D and AI-driven innovation with an investment of €200 million by 2028.
Concept Medical Unveils Landmark SirPAD Trial at ACC 2026, Advancing PAD Treatment
Concept Medical Inc. (CMI), a global leader in drug-delivery technologies for vascular interventions, has announced the presentation of the world’s largest randomized controlled trial evaluating a sirolimus-coated balloon (SCB) for peripheral artery disease (PAD) at the ACC 2026 Scientific Sessions.
AstraZeneca Advances Rare Disease Pipeline with Positive HPP Phase III Data
Alexion, AstraZeneca Rare Disease, has reported positive results from its global Phase III clinical programme evaluating efzimfotase alfa (ALXN1850) in patients with hypophosphatasia (HPP), a rare inherited metabolic disorder.
AviadoBio Advances AVB-101, Starts New Cohort in Phase 1/2 ASPIRE-FTD Trial
AviadoBio advances AVB-101 gene therapy with a new Phase 1/2 ASPIRE-FTD cohort, reporting encouraging early data, securing strategic funding and regaining full programme rights.
Biogen to Acquire Apellis, Expands Immunology and Rare Disease Portfolio
Biogen to acquire Apellis for USD 5.6 billion, adding EMPAVELI and SYFOVRE to expand its immunology, rare disease and nephrology portfolio and drive long-term growth.
Lilly to Acquire Centessa in USD 6.3 Billion Deal, Expands Neuroscience Pipeline
Eli Lilly and Company has announced a definitive agreement to acquire Centessa Pharmaceuticals plc, strengthening its neuroscience portfolio and advancing next-generation therapies for sleep-related and neurological disorders.
India Emerges as High-Velocity Biopharma Innovation Hub: Endiya Report
India’s biopharma sector gains momentum as policy support, innovation and cost advantages position the country as a global R&D hub.
Novavax Appoints Robert Walker as EVP and Head of R&D
Novavax appoints Robert Walker as EVP and Head of R&D, bringing 30+ years of experience to advance its pipeline, Matrix adjuvant innovation and advancement of the company pipeline.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy